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Abstract
Background: Shared decision making is a stated aim of several healthcare systems. In the area of cancer, patients’
views have informed policy on screening and treatment but there is little information about their views on
diagnostic testing in relation to symptom severity.
Methods: We used the technique of willingness-to-pay to determine public preferences around diagnostic testing
for colorectal, lung, and pancreatic cancer in primary care in the UK. Participants were approached in general practice
waiting rooms and asked to complete a two-stage electronic survey that described symptoms of cancer, the likelihood
that the symptoms indicate cancer, and information about the appropriate diagnostic test. Part 1 asked for a binary
response (yes/no) as to whether they would choose to have a test if it were offered. Part 2 elicited willingness-to-pay
values of the tests using a payment scale followed by a bidding exercise, with the aim that these values would provide
a strength of preference not detectable using the binary approach.
Results: A large majority of participants chose to be tested for all cancers, with only colonoscopy (colorectal cancer)
demonstrating a risk gradient. In the willingness-to-pay exercise participants placed a lower value on an X-ray (lung
cancer) than the tests for colorectal or pancreatic cancer and X-ray was the only test where risk was clearly related to
the willingness-to-pay value.
Conclusion: Willingness-to-pay values did not enhance the binary responses in the way intended; participants
appeared to be motivated differently when responding to the two parts of the questionnaire. More work is needed to
understand how participants perceive risk in this context and how they respond to questions about willingness-to-pay.
Qualitative methods could provide useful insights.
Keywords: Willingness-to-pay, Cancer, Diagnostic tests, Primary health care
Background
Shared decision making is a stated aim of several health-
care systems [1, 2]. Involving patients in critical deci-
sions about their care is regarded as not only ethically
correct but also as a way of improving quality and
“avoiding unwanted and costly medical interventions”
[3]. In the UK the philosophy of “no decision about me,
without me” has been promoted by the Department of
Health [4] and has been applied to many aspects of
patient care. However, fully shared decisions can only be
made if the asymmetry of information between clinicians
and patients is more balanced. Recently, the current im-
balance has begun to shift, encouraged by a greater will
on the part of clinicians and an increase in readily avail-
able information accessible to patients, both from the
National Health Service (NHS) and elsewhere.
One notable area where shared decision making has
been adopted actively is cancer. Research on patients’
views has informed policy on screening [5] and treat-
ment [6] in accordance with referral guidelines devel-
oped by the National Institute for Health and Care
Excellence (NICE) [7]. Such information is important, as
care plans that incorporate patients’ preferences are
more likely to be successful in terms of acceptability and
may lead to more efficient use of resources. However,
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one gap in the evidence is information about patients’
views on testing for cancer with respect to risk: how
serious do symptoms have to be, in terms of indicating
cancer, for patients to consider a particular test to be
worthwhile? The lifetime prevalence of cancer in the UK
is more than 30 % [8] and despite falling death rates the
fear of cancer is known to be high among the general
population [9]. Early diagnosis may improve survival
[10] but many early symptoms of cancer, for example,
cough, diarrhoea, and headache, far more often indicate
a benign condition. General practitioners are faced with
the challenge of deciding which patients with such
symptoms to refer for diagnostic testing, relying largely
on their expertise and limited national guidelines [7].
The risk of failing to investigate a potentially serious
symptom has to be weighed against the need to avoid
unnecessary anxiety, inconvenience, side-effects and cost
from inappropriate investigation.
The study described here is part of a larger study
reported more fully elsewhere [11], which used a survey of
primary care attenders to investigate preferences for can-
cer investigation. Three contrasting cancers were chosen
as exemplars - colorectal, lung and pancreas – because of
their variation in symptoms, type and accessibility of test,
treatment, and prognosis. Here, we describe a willingness-
to-pay component of the survey, which was designed to
enhance the results of the main survey: if the same num-
ber of participants opted to be investigated for a particular
cancer irrespective of risk level, could the values offered in
the willingness-to-pay exercise be used to refine these
responses and identify a threshold risk level below which
testing was not regarded as worthwhile?
Willingness-to-pay has been used extensively to obtain
patient and public valuations for a variety of goods and
services in many diverse settings [12]. Despite consider-
able methodological research into the use of different
willingness-to-pay techniques [13] no consensus has
emerged as to best practice and it is likely that different
methods suit different situations and patient groups [14,
15]. The simplest form of value elicitation is to use an
‘open-ended’ approach whereby the respondent is asked
to provide a valuation without any prompting or context;
more sophisticated, is a ‘payment scale’ approach where a
list of feasible values is offered and the respondent
chooses from the list. A bidding approach, which is more
refined, has generally come to be preferred to both of
these [16, 17]. This method requires the respondent to
accept or reject a starting bid (value), which is increased
or decreased according to the response and the process
continues until a final value is determined. Although this
is often a preferred method there is evidence suggesting
that responses in a bidding approach tend towards the
point at which the bidding starts (starting point bias)
[18–20]. This can lead to biased results.
The aim of this study was to develop and administer a
willingness-to-pay questionnaire that could be used to
elicit the relative values that patients place on diagnostic
testing for lung, pancreatic and colorectal cancers. We
aimed to identify a risk threshold for each cancer that
would indicate when patients choose to be tested in
preference to watchful waiting.
Methods
Study design
We developed a vignette-based survey with a willingness-
to-pay component to determine the likelihood that
patients would choose to be tested for colorectal, lung,
and pancreatic cancer, using various levels of risk. The key
question of what proportion of the population would
choose to be tested at each risk level for each cancer was
addressed using a simple 'yes/no' alternative. Those
responding ‘yes’ to a test proceeded to a willingness-
to-pay exercise with the aim of identifying a strength of
preference around the binary choice. Cookson suggests
that willingness-to-pay exercises that aim to elicit true, ab-
solute values are unreliable because of “budget constraint
bias”, where the value given is inflated because of the close
focus placed on a particular service [21]; comparative
willingness-to-pay may be a way of avoiding this. This
study adopted the latter technique, with the aim of identi-
fying relative values to differentiate between ‘yes’ re-
sponses by risk level. The survey was designed specifically
for this study and was administered using an electronic
touch screen tablet computer (an iPad). The iPad applica-
tion software was custom built, which gave us consider-
able scope and flexibility in the design. We obtained ethics
approval from the South West (Southmead) National
Research Ethics Service committee (ref 11/SW/0055). Par-
ticipants provided oral informed consent.
Survey design
The survey contained three components. The first section
asked for information about participant characteristics, in-
cluding age, sex, income, education, employment status,
ethnicity, experience of cancer (self and family member or
close friend), and convenience of the nearest main hos-
pital. Screen shots showing details of the way these ques-
tions were asked are included in the Appendix (Fig. 3).
Secondly, we used vignettes to ascertain participants’ at-
titudes towards testing for cancer. We developed twelve
separate vignettes, one for each combination of the three
cancers (colorectal, lung, and pancreas) and four different
risk levels (1 %, 2 %, 5 %, 10 %). The content of the
vignettes was informed by current guidelines and clinical
experts on the team. We also undertook qualitative inter-
views with patients referred for symptoms suspicious of
cancer [22], and these were used to validate the vignettes’
depiction of the three diagnostic pathways as experienced
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by patients. Each vignette contained a description of
symptoms, the chance that these might indicate cancer –
presented as a percentage, ratio, and pictorially – infor-
mation about the diagnostic test that would be used,
likely treatment, and an indication of the prognosis.
The information provided in the vignettes is summarised in
Table 1. For each participant, one of the twelve vignettes
was generated randomly, thus avoiding any ordering effect,
and the respondent was asked to imagine they were in the
situation described in the scenario. They were then asked
whether they would choose to have the diagnostic test if it
were offered.
Following a ‘yes’ response to the question about test-
ing, participants proceeded automatically to the third
section of the survey – the willingness-to-pay exercise.
The design of this part of the survey was informed by
experts in the team and with reference to published
costs of tests. The survey and the values included were
tested on a sample of participants using the technique of
verbal probing [23] to check that respondents inter-
preted the question correctly, and understood why it
was being asked. Two rounds of verbal probing were
carried out, the first on 13 participants and the second
on five. Further pilot testing ensured that the exercise
would not be too burdensome. Feedback from the verbal
probing was used to refine the content: data from the
first round indicated that respondents did not fully
understand the concept of opportunity cost so the word-
ing was changed to convey the idea of sacrifice. Subse-
quent testing in round 2 showed this change was
successful. To mitigate starting point (or anchoring) bias
we designed a two-part exercise in which respondents
were first presented with a payment scale and the re-
sponse to that question established the starting point of
a bidding process. The starting point was generated ran-
domly from a selection within the range of the scale
chosen, and the participants could then bid up or down
from the starting point. This mechanism is illustrated in
Fig. 1, using an example where a participant selects the
payment scale £101 to £300. The starting point for the
bidding is randomly selected by the software from £125,
£200, £250 and £300; in this example £200 is selected.
The participant is then able to bid up as far as £300 or
down to below £125, with five possible end points. In
total, 18 end points were used, five for each of the lower
three bands (£1 to £100, £101 to £300, and £301 to £700)
and three for the “more than £700” band. Within each
band, the difference between each end point and the one
immediately higher increased as the value increased so
that proportional differences were roughly similar [24].
At the beginning of the task, when presenting the pay-
ment scales, we used reference goods to help participants
think about the value of a diagnostic cancer test (see Fig. 2).
We chose a selection of ‘lifestyle’ goods and services, seen
as being ‘desirable’ though not essential, and which could
conceivably be sacrificed to pay for healthcare. Wording
was carefully chosen to encourage them to think in terms
of sacrifice – that is, what they might be prepared to give
up or go without in order to have a test [25].
It is known that some individuals find it hard to place
a value on healthcare, particularly in the context of a
system of universal coverage as in the UK, and moreover
some individuals feel it is unethical to expect them to
provide a valuation. To accommodate these views the
payment scale offered an option of “I would not pay any-
thing for the test”. If this was selected they were then
asked a further question about their reason for this view
with the choices of “I cannot afford anything extra”, “I
do not believe I should pay for healthcare”, and “It is too
difficult to put a value on health”.
Throughout the development of the survey we piloted
the wording and layout of all components with a patient
Table 1 Summary of content of 12 vignettes: one for each combination of cancer and risk level
Colorectal Lung Pancreas
symptoms for 1 % risk Diarrhoea on most days Coughing on most days…unusually tired Some stomach pain on most days…
lost a few pounds (~1.5-3 kg) in weight
symptoms for 2 % risk Diarrhoea and stomach pain
on most days
Coughing on most days…a little out of
breath walking up hills…lost a few pounds
(~1.5-3 kg) in weight
Some stomach pain on most days…
lost half a stone (3.2 kg) in weight
symptoms for 5 % risk Unusually tired…blood test
shows anaemia
Coughing on most days…coughed
blood once
Continuous stomach pain…lost half
a stone (3.2 kg) in weight
symptoms for 10 % risk Intermittent bleeding from
the back passage (rectal bleeding)…
blood test shows anaemia
Coughing on most days…coughed
blood a few times…lost half a stone
(3.2 kg) in weight
Continuous stomach pain…lost 1 stone
(6.4 kg) in weight
test/investigation Colonoscopy Chest x-ray Ultrasound scan followed by CT scan
treatment Surgery and chemotherapy “Difficult to treat” “Difficult to treat”
prognosis/outlook Early diagnosis may improve
outcome
Early diagnosis may improve outcome Early detection does not necessarily
improve survival
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and public involvement group using the technique of
verbal probing [23]. Feedback from these sessions was
used to refine and improve the content.
Survey administration
The survey was administered by researchers in general
practice waiting areas. We targeted a susceptible popula-
tion – that is, those at greater risk of cancer who would
be likely to seek health care help and advice (GP at-
tenders aged 40 and over). General practices in three
geographical areas (Bristol & South Gloucestershire,
Devon, and the East of England) were included and
practices were purposively sampled to achieve an overall
mix of urban and rural, and a range of socio-economic
statuses. Data collection took place at 26 practices at dif-
ferent times of the day and week between December
2011 and August 2012.
Participants could complete up to three vignettes, one
for each cancer. The first vignette was randomly generated
from all 12 possibilities (three cancers, four risk levels),
the second from the eight that related to the two
remaining cancers, and the third from the four relating to
the final cancer.
When data collection was complete we conducted a
test-retest exercise in a different practice using a con-
venience sample of 48 volunteers who agreed to return
two weeks later. The random generation of vignettes
was removed from the survey for the second stage of
this exercise to ensure the two tests were identical.
Analysis
Data were electronically downloaded directly from the
iPads at the end of each session. Participant characteristics
were explored descriptively and the age/sex profile was
compared with that of England as a whole and general
practice attenders. Responses to the choice of whether to
be tested were analysed descriptively and using logistic re-
gression to establish the extent to which risk played a part
in participants’ decisions.
Fig. 1 Schema illustrating the two-part willingness to pay exercise. Choice of payment scale leads to a bidding process with the starting point randomly
generated from four values within the band
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The data from the willingness-to-pay exercise were ana-
lysed to explore whether they could be used to inform the
strength of preference about the simple 'yes/no' choice. We
therefore investigated the extent to which willingness-to-
pay values differed according to risk. We explored this de-
scriptively using means and medians, and tested the rela-
tionship between the willingness-to-pay values and risk
using regression analysis. A one-way analysis of variance,
with three degrees of freedom, was conducted to investigate
the difference in mean willingness-to-pay across all risk
levels, for each cancer.
Analysis was carried out using Stata v13.1 statistical
software and Microsoft Office Excel 2013.
Results
Participant characteristics
A total of 3,469 participants took part, completing 6,930 vi-
gnettes. The characteristics of the participants are shown in
Table 2. The age/sex profile of responders is similar to that
of the consulting population in England [26]. As expected,
when compared with the general population of England the
sample was under-represented in terms of younger men
(17 % vs 27 % aged 40–59), and over-represented in respect
of older women (15 % vs 11 % aged 60–69), and for all
elderly people (29 % vs 24 % aged 70 and over) [27]. The
respondents were largely white British and nearly half were
retired; 15 % had previously been diagnosed with cancer
and 75 % had a family member or close friend who had
experienced cancer.
Binary responses
Detailed results of the responses to the 'yes/no' question
about whether to opt for a test have been reported else-
where [11]. Table 3 shows the number of participants
choosing to be investigated at each risk level for each
cancer. A large majority (88 %) of participants chose to
be referred for a test; this was slightly lower in the low
risk (1 %) group and higher in the high risk (10 %)
Fig. 2 Screen shot of the payment scale exercise showing the use of reference goods
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group, but the difference was very small (87 % vs 89 %).
Colonoscopy (colorectal cancer) had a lower uptake than
chest X-ray (lung cancer) and ultrasound/CT scan (pan-
creatic cancer) and displayed the greatest risk gradient.
These observations were confirmed by the results of the
logistic regression analysis, which controlled for patient
characteristics.
Willingness-to-pay
The results of the willingness-to-pay exercise are pre-
sented in Tables 4, 5 and 6. Table 4 gives the number
and percentage of participants who selected each pay-
ment scale, by cancer and by risk level and Table 5 gives
the values indicated in the bidding exercise. Results for
each cancer separately are based on all responses, but
because participants could respond to up to three vi-
gnettes, results for all cancers together use each partici-
pant’s first response so as to reduce differential selection
bias. Responses covered the entire payment range
offered for all cancers and all risk levels, though 68 % of
participants bid up to the highest value within the range
of the payment scale chosen.
The results show that participants placed a lower value
on an X-ray for lung cancer than the tests for colorectal
or pancreatic cancer; the regression analysis in Table 6,
which shows the best-fit logistic regression models, indi-
cate that, controlling for other factors, there was a differ-
ence of about £51 (95 % CI: £14 to £87) in the mean
willingness-to-pay between an X-ray and a colonoscopy
and slightly less between an X-ray and the tests for
pancreatic cancer. In general, testing was valued more
highly when risk was high than when it was low,
though the increase is not monotonic in the case of
colorectal and pancreatic cancers (Tables 5 and 6).
This may be related to the lack of a clear gradient for
these two, as evidenced by testing for a difference in
mean willingness-to-pay by risk level (p-values: colo-
rectal 0.71; pancreas 0.91).
Around one fifth of respondents chose “I would not
pay anything” when completing the payment scale exer-
cise. Of these, one half said they did not believe they
should pay for health care and one third said they could
not afford to pay. Comparing the lowest risk level (1 %)
with the highest (10 %), more individuals reported not
being able to pay at the higher level (32 % vs 26 %) and
more said they did not think they should pay at the
lower level (59 % vs 52 %).
Factors influencing responses to individual cancers
Previous analysis of responses to the ‘yes/no’ question of
whether participants chose to be tested indicated that
age was an important factor in all three cancer models
[11]. Other variables affecting this decision were travel
time to nearest hospital (colorectal and lung), whether a
family member or close friend had previously been diag-
nosed with cancer (colorectal and lung) and income
(colorectal and pancreas). The willingness-to-pay exercise
indicated a rather different set of variables influencing the
values placed on the tests: age did not appear as a factor
in any of the three models and neither did travel time
(Table 6). Three variables did however contribute to the
willingness-to-pay values in all three tests: those with a
Table 2 Participant characteristics
Characteristic Category n %
Age group n = 3452 40-59 1519 44.0
60-69 945 27.4
70+ 988 28.6
Sex n = 3461 male 1457 42.1
female 2004 57.9
Income n = 2958 <£10,000 720 24.3
£10,000 - £25,000 1166 39.4
£25,001 - £40,000 581 19.6
£40,001 - £75,000 319 10.8
>£75,000 172 5.8
Ethnicity n = 3453 White British 3,096 89.7
White Other 159 4.6
Mixed 40 1.2
Asian or Asian British 90 2.6
Black or Black British 46 1.3
Chinese 10 0.3
Other Ethnic Group 12 0.4
Education n = 3388 None 1,001 29.6
GCSE or equivalent 781 23.1
Vocational / ‘A’ level 850 25.1
Degree and higher 756 22.3
Employment n = 3446 Retired 1,673 48.5
Not in paid employment 379 11.0
Working part time 607 17.6
Working full time 787 22.8
Cancer diagnosis – self
n = 3463
Yes 522 15.1
No 2941 84.9
Cancer – family/ close
friend n = 3465
Yes 2597 75.0
No 868 25.1
Convenience of hospital
n = 3461
Very convenient 1,388 40.1
Quite convenient 1,621 46.8
Quite inconvenient 323 9.3
Very inconvenient 129 3.7
Travel time to hospital
n = 3463
<0.5 h 1,759 50.8
0.5 – 1 h 1,458 42.1
>1 h 246 7.1
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higher income, particularly those in the highest bracket,
were prepared to pay more for testing, as were the more
highly educated, and a previous diagnosis of cancer
increased the valued placed on a test by between £63
(95 % CI: £13 to £114) (lung) and £73 (95 % CI: £22 to
£124) (colorectal). Additionally, the values placed on an
X-ray for lung cancer were affected by a family member
or close friend having been diagnosed with cancer and
employment status. Males were prepared to pay more for
testing for pancreatic cancer than were women.
Test-retest
Analysis of the test-retest data suggested a good level of
agreement in terms of the binary choice question: 47
(99 %) of the 48 who took part gave the same response as
to whether they would choose to be tested. The level of
agreement for both parts of the willingness-to-pay elem-
ent was lower. Forty-three of the 48 respondents entered
the willingness-to-pay exercise on both occasions and
chose a payment scale. Of these, 25 (58 %) chose the same
band on both occasions. Forty-two participants gave two
valid willingness-to-pay values from the bidding process
and 14 (33 %) gave the same exact value at re-test.
Discussion
Key findings
The aim of this willingness-to-pay exercise was to en-
hance the responses to a simple 'yes/no' question about
testing for cancer, by indicating a strength of preference.
We hypothesised that we might be able to identify a
threshold level of risk below which patients would prefer
to wait and see how symptoms develop before being
referred for further investigation. Although the over-
whelming majority of respondents opted for testing for
the three cancers at all levels of risk included, the re-
sponses to the willingness-to-pay exercise did not aug-
ment the results of the binary question as anticipated; in
fact the results suggest that participants treated the two
parts of the survey rather differently. The 'yes/no' com-
ponent of the survey indicated a risk gradient in the case
of colorectal cancer, which was not seen in the
willingness-to-pay values given to pay for a colonoscopy,
Table 3 Number (%) choosing to be investigated by cancer and risk level
Colorectal Lung Pancreas All three cancers (first vignette only)
Risk
level
Number of
responses
Number (%) choosing
to be tested
Number of
responses
Number (%) choosing
to be tested
Number of
responses
Number (%) choosing
to be tested
Number of
responses
Number (%) choosing
to be tested
1 % 572 462 (81 %) 581 533 (92 %) 582 525 (90 %) 898 782 (87 %)
2 % 569 485 (85 %) 571 531 (93 %) 580 527 (91 %) 838 738 (88 %)
5 % 580 496 (86 %) 589 543 (92 %) 572 526 (92 %) 873 764 (88 %)
10 % 570 508 (89 %) 582 537 (92 %) 582 529 (91 %) 860 768 (89 %)
2291 1951 (85 %) 2323 2144 (92 %) 2316 2107 (91 %) 3469 3052 (88 %)
Table 4 Number and percentage of respondents selecting each willingness-to-pay band by cancer (all responses) and by risk level
(first response only)
Colorectal Lung Pancreas All three cancers (first response only)
£1-£100 630 (35 %) 774 (39 %) 691 (36 %) 1,030 (37 %)
£101-£300 382 (21 %) 400 (20 %) 397 (20 %) 541 (20 %)
£301-£700 186 (10 %) 180 (9 %) 197 (10 %) 262 (9 %)
over £700 287 (16 %) 278 (14 %) 312 (16 %) 405 (15 %)
would not pay 311 (17 %) 346 (17 %) 340 (18 %) 527 (19 %)
1,796 1,978 1,937 2,765
1 % 2 % 5 % 10 %
£1-£100 295 (42 %) 244 (36 %) 242 (36 %) 252 (36 %)
£101-£300 139 (20 %) 127 (19 %) 129 (19 %) 146 (21 %)
£301-£700 58 (8 %) 71 (10 %) 62 (9 %) 71 (10 %)
over £700 83 (12 %) 102 (15 %) 102 (15 %) 118 (17 %)
would not pay 124 (18 %) 137 (20 %) 146 (21 %) 120 (17 %)
699 681 681 707
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but there was evidence that risk influenced willingness-
to-pay values for testing for lung cancer. Furthermore,
the participant characteristics that affected the decision
to opt for a test were different than those affecting the
willingness-to-pay values.
Explanations for the findings
In general, the willingness-to-pay values obtained did not
differentiate across risk levels as much as hypothesised. It
is possible that the known “fear of cancer” may have con-
tributed to this, indeed this was indicated in the yes/no
part of the questionnaire where results suggested that pa-
tients would opt for testing even at very low levels of risk.
The willingness-to-pay values obtained suggest that
risk is an important consideration when patients are
deciding whether to accept the offer of a test for cancer
of the lung but not colorectal or pancreas, a finding at
odds with those of the binary 'yes/no' decision, where
risk was only evident in colorectal cancer. Colorectal
cancer involves the most invasive test, which may
explain this finding, but it would seem that in the
willingness-to-pay exercise participants may have dis-
criminated according to neither the burden of the test
nor the prognosis (pancreatic cancer having the worst
likely outcome), but possibly their perception of the cost
of the test. They valued a chest X-ray more highly if the
risk of cancer was high (£365 at 10 % risk) and lower if
the risk was low (£305 at 1 % risk) and there was a clear
gradient (p-value 0.049). This was not the case with the
more expensive tests where there was no evidence of an
overall gradient despite the value placed on a CT scan
for pancreatic cancer at the 10 % risk level being some-
what higher than the value at 1 %. The tests were
described in detail in the vignettes so it is possible that
many participants recognised that a chest X-ray is less
costly than a colonoscopy and a CT scan. This confirms
the belief that willingness-to-pay questions tend not to
be sensitive to the size or scope of benefits [28] but is
counter to the finding that people tend to state a similar
amount for any reduction in risk of death or injury [29].
This raises the question of what people are actually
valuing when they answer a willingness-to-pay question.
Our hypothesis was that the willingness-to-pay exercise
could be used to discriminate between cancers and risk
levels more sensitively than a binary choice of whether
to be tested or not. However, it would seem that partici-
pants viewed the two parts of the questionnaire separ-
ately and differently: the initial choice of whether to be
tested appears to have been driven by the burden placed
on them in undergoing the diagnostic test, illustrated by
greater reservation about agreeing to a colonoscopy than
the other tests, whereas the willingness-to-pay compo-
nent appears to reflect people’s perception of the cost
burden of the test, as a chest X-ray is by far the least
expensive of the three. While the main aim of our study
was to make comparisons across cancers and risk levels
it is useful to reflect on the absolute levels of the
willingness-to-pay values in comparison to those found
in similar studies. Marshall et al. [5] compared physician
and patient preferences for different methods of screen-
ing for colorectal cancer in Canada and the US. The
values obtained ranged from US$111 (equivalent to £245
inflation adjusted) to C$232 (£662) depending on the
type of test and in another US-based study to determine
the value of time and discomfort of a colonoscopy, Jonas
et al. [30] reported a mean value of US$263 (£563). In
the UK Frew et al. [31] compared different methods of
Table 5 Mean (SD) and median (IQR) willingness-to-pay values,
by cancer and risk level
n Mean (SD) £ Median (IQR) £
Colorectal
1 % 354 380 (348) 300 (100 to 700)
2 % 351 393 (351) 300 (100 to 700)
5 % 373 367 (351) 270 (100 to 700)
10 % 385 367 (343) 270 (100 to 700)
1463 377 (348) 300 (100 to 700)
p-value 0.71
Lung
1 % 401 305 (326) 100 (100 to 300)
2 % 403 339 (336) 270 (100 to 503)
5 % 399 360 (349) 270 (100 to 700)
10 % 412 365 (346) 270 (100 to 700)
1615 342 (340) 224 (100 to 670)
p-value 0.049
Pancreas
1 % 389 371 (355) 224 (100 to 700)
2 % 405 367 (336) 300 (100 to 700)
5 % 378 375 (352) 270 (100 to 700)
10 % 401 385 (358) 300 (100 to 700)
1573 374 (350) 270 (100 to 700)
p-value 0.91
all cancers (first response only)
1 % 567 312 (327) 100 (100 to 300)
2 % 534 366 (347) 270 (100 to 700)
5 % 529 360 (347) 270 (100 to 700)
10 % 573 377 (351) 270 (100 to 700)
2203 353 (344) 224 (100 to 700)
p-value 0.0075
NOTE: p-values were obtained from the one-way analysis of variance, with
three degress of freedom, conducted to compare the effect of risk level
on willingness-to-pay
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Table 6 Logistic regression: factors influencing the value of willingness-to-pay. Best fit logistic regression models for each cancer separately and all cancers together
£ All cancers togethera Colorectal (colonoscopy) Lung (chest x-ray) Pancreas (Ultrasound / CT scan)
Variable
(reference
category)
Coeff (se) p-value 95 % CI Coeff (se) p-value 95 % CI Coeff (se) p-value 95 % CI Coeff (se) p-value 95 % CI
Cancer
(colorectal)
0.0012
Lung −50.80 (18.67) 0.0070 (−87.43 to −14.18)
Pancreas 8.56 (19.37) 0.6590 (−29.44 to 46.55)
Risk (1 %) 0.0206
2 % 65.53 (21.07) 0.0020 (24.21 to 106.85)
5 % 49.71 (21.29) 0.0200 (7.95 to 91.47)
10 % 88.15 (20.93) <0.0001 (47.10 to 129.20)
Household
Income
(<£10,000)
<0.0001 <0.0001 <0.0001 <0.0001
£10,000 -
£25,000
46.96 (22.22) 0.0350 (3.39 to 90.53) 23.06 (27.35) 0.3990 (−30.58 to 76.71) 48.75 (26.63) 0.0670 (−3.48 to 100.99) 42.47 (27.29) 0.1200 (−11.05 to 96.00)
>£25,000 153.42 (25.43) >0.0001 (103.55 to 203.30) 132.99 (28.73) <0.0001 (76.62 to 189.36) 150.42 (29.83) <0.0001 (91.90 to 208.93) 145.28 (28.86) <0.0001 (88.66 to 201.90)
Education <0.0001 <0.0001 0.0208 <0.0001
GCSE or
equivalent
−21.07 (23.59) 0.3720 (−67.33 to 25.20) −9.85 (28.87) 0.7330 (−66.50 to 46.79) −0.22 (27.73) 0.9940 (−54.61 to 54.17) −41.75 (28.49) 0.1430 −97.64 to 14.14)
A-level or
equivalent
21.48 (22.91) 0.3490 (−23.46 to 66.43) 33.44 (28.13) 0.2350 (−21.75 to 88.62) 35.68 (27.42) 0.1930 (−18.10 to 89.46) −17.51 (28.02) 0.5320 −72.47 to 37.45)
Higher
education
95.22 (24.36) <0.0001 (47.44 to 143.01) 133.53 (29.96) <0.0001 (74.74 to 192.31) 72.97 (29.08) 0.0120 (15.93 to 130.01) 86.06 (29.78) 0.0040 (27.64 to 144.49)
Cancer
diagnosis
(yes)
0.0033 0.0048 0.0138 0.0092
No −63.48 (21.67) 0.0030 (−105.98 to −20.98) −73.04 (25.93) 0.0050 (−123.92 to −22.17) −63.63 (25.92) 0.0140 (−114.47 to −12.79) −70.71 (27.18) 0.0090 (−124.02 to −17.39)
Employment
(Retired)
0.0137 0.0488
Not in paid employment −76.57 (27.55) 0.0060 (−130.60 to −22.53) −82.45 (32.22) 0.0100 (−145.64 to −19.25)
Working
part time
−40.55 (21.33) 0.0570 (−82.37 to 1.27) −43.00 (25.33) 0.0900 (−92.70 to 6.70)
Working
full time
−3.39 (21.22) 0.8730 (−45.01 to 38.23) −20.24 (23.86) 0.3960 (−67.05 to 26.57)
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Table 6 Logistic regression: factors influencing the value of willingness-to-pay. Best fit logistic regression models for each cancer separately and all cancers together (Continued)
Family cancer
(yes)
0.0276
No −46.89 (21.36) 0.0280 −88.78 to −5.00)
Sex (male) 0.0298
Female −40.09 (18.49) 0.0300 −76.37 to −3.81)
aBased on first response only to avoid mote than one respinse from each participant
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eliciting the willingness-to-pay for a faecal occult blood
(FOB) test and a flexible sigmoidoscopy (FS) for colorec-
tal cancer screening with results ranging from £86
(£136, inflation adjusted) for FS to £130 (£205) for FOB.
In comparison to this, Nuemann et al. [17] obtained
somewhat higher values in their US study for pre-
dictive testing: for breast and prostate cancer these
ranged from US$508 (£904) for an imperfect test for
breast cancer when the risk is 10 % to US$622
(£1007) for a perfect test for prostate cancer when
the risk is 25 %. Our results of £305 to £393 across
all cancers and risk levels fall towards the lower end
of these, closer to the UK study results than those
from North America.
Methodological considerations
A variety of willingness-to-pay methods have been used
in different settings and different patient groups [12]. In
this study we used a bidding approach; furthermore, to
mitigate the effect of any possible starting point bias we
employed a two-part approach with each participant
effectively selecting their own starting point. To our
knowledge, this is a novel approach, made possible be-
cause of the mode of administration and the electronic
nature of the questionnaire. However, in avoiding one
methodological difficulty we have arguably introduced
another. The bidding exercise was designed to restrict
participants to the boundaries of the payment scale they
chose in the first part of the willingness-to-pay exercise.
This decision was largely driven by concern over ethics:
it was considered ‘unfair’ to allow respondents to bid
above/below the top/bottom value of the scale they had
chosen. In fact, we found that 68 % of participants bid
up to the highest value, leaving the unanswered question
of what would have happened if they had been allowed
to go beyond that value. This, in part, may explain the
poor result in the relevant part of the test-retest exercise
because once the participant had chosen a different pay-
ment scale in the retest, which 40 % did, it was impos-
sible for them to identify the same final value as in the
initial exercise.
In designing our study we were conscious of the
phenomenon of ‘prominent’ numbers and we felt that
the two-part design might mitigate this. In fact, analys-
ing the results of the test-retest exercise we found that
all participants who chose exactly the same value on
both occasions had chosen a ‘prominent’ number: £0,
£100, £300, £700 or £1000. This highlights the need for
a better understanding of the role of ‘prominent’ num-
bers in such studies and has implications for the design
of future studies.
We included reference goods in the payment scale ex-
ercise to help participants think about the value of a test.
The verbal probing exercise did not throw up any
consensus concerns about the use of reference goods or
the choice of goods but there were some interesting in-
dividual comments: “You are given a few ideas to give
you the value of the cost”, “I think health is more import-
ant than material things” and “At my age we already
have most things we need – furniture etc.” However,
when asked how easy or hard it was to put a value on
the test none of the respondents mentioned that the ref-
erence goods helped. Whilst it seems useful to have
benchmark reference goods for respondents to use our
experiences suggest these are not essential; if they are
included they must be chosen carefully and must be
relevant to the population being surveyed.
Limitations
The technique of willingness-to-pay is a conceptually
attractive method of eliciting valuations and preferences.
If responses reflect the true value that a population places
on an intervention such as diagnostic testing the value
can be compared with cost in a ‘purer’ way than any other
outcome and used to make decisions about allocative effi-
ciency. However, the results of this study show that many
people find it difficult to think in terms of the value of
benefit offered rather than what the intervention involves,
and this is likely to be particularly true in a system of uni-
versal health insurance such as the NHS in England.
While we were unable to use the results of this study as
intended, they do reveal interesting unanswered questions
which should be explored further. Qualitative methods
could be employed to understand more about the thought
processes and motivation of respondents as they complete
such a survey; although some limited work has been
done in this area [24, 32] there is a clear gap in our
knowledge that needs to be closed in order to suc-
cessfully exploit the full potential of willingness-to-
pay as a technique for eliciting true valuations.
Conclusion
The willingness-to-pay exercise reported here success-
fully obtained valuations for cancer testing from a large
and diverse sample of the UK consulting population. A
risk gradient was found only in the case of an X-ray for
lung cancer, with higher values reflecting greater risk.
This was inconsistent with responses to the question of
whether to be tested or not, which suggested risk af-
fected testing preferences only in the case of colorectal
cancer. More investigation is needed to understand how
patients perceive and respond to risk in this context, and
how best to develop the use of willingness-to-pay tech-
niques, which have the potential to provide good quality
evidence which could enhance decision making in the
provision of health care services.
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Appendix
Fig. 3 Screen shots showing questions about participant characteristics
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